Komori
Vital Ksk Holdings (3151) · TargetRestated

A Profit-Generating Structure in the Era of 80% Generic Drug Use

First written in FY2016. 20 of 23 entries say "Restated". Latest entry: FY2022.

23entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019-Q3RestatedFY2020-Q1 – FY2021-Q3RestatedFY2022-Q1 – FY20222016: 320162017: 320172018: 320182019: 420192020: 420202021: 420212022: 22022
Same theme, other companies
Industry-leading position as a prescription pharmaceutical wholesaler and strengthening of the business foundationA theme 3 companies write about · 0 as a headwind · 4 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「In the pharmaceutical wholesaling business, the company will establish a business structure that continues to generate profit through efficiency improvements even in a low-growth prescription pharmaceutical market.」

    The company continues, under the Fifth Medium-Term Management Plan, to pursue the establishment of a pharmaceutical wholesaling business structure that continues to generate profit through efficiency improvements even in a low-growth environment.
  2. FY2022-Q3RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to set, in the final year of the Fourth Medium-Term Management Plan, the establishment of a pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment as a priority.
  3. FY2022-Q2RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to set, in the final year of the Fourth Medium-Term Management Plan, the establishment of a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment as a priority.
  4. FY2022-Q1RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to set, in the final year of the Fourth Medium-Term Management Plan, the establishment of a pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment as a priority.
  5. FY2021ReframedAnnual report

    「In the fiscal year ending March 2022, the final year of the Fourth Medium-Term Management Plan, the company will make the turnaround of its core prescription pharmaceutical wholesaling business its top priority.」

    In addition to the previous priority of establishing a structure that generates profit in a low-growth environment, the company explicitly identifies the turnaround of its core business as its top priority for the fiscal year ending March 2022.
  6. FY2021-Q3RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  7. FY2021-Q2RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  8. FY2021-Q1RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company has reconfirmed, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  9. FY2020RestatedAnnual report

    「1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a profit-generating structure in a low-growth environment, replacing the previous wording referring to an era when generic drugs account for 80% of the market.
  10. FY2020-Q3RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  11. FY2020-Q2RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  12. FY2020-Q1RestatedAnnual report

    「Priority issue: 1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company continues to pursue, as a priority issue under the Fourth Medium-Term Management Plan, the establishment of a profit-generating structure in a low-growth environment, replacing the previous wording referring to an era when generic drugs account for 80% of the market.
  13. FY2019ReframedAnnual report

    「1. Establish a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment」

    The company has changed the wording from the previous medium-term vision of an era when generic drugs account for 80% of the market to establishing a pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment.
  14. FY2019-Q3RestatedAnnual report

    「The company has established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company continues to set the building of a profit-generating structure based on an era when generic drugs account for 80% of the market as a priority in the final year of the medium-term management plan.
  15. FY2019-Q2RestatedAnnual report

    「Under this long-term vision, the company has established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company continues to set, in the final year of the plan, its target of building a profit-generating structure based on an era when generic drugs account for 80% of the market.
  16. FY2018RestatedAnnual report

    「Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market.」

    The company continues to set its target of building a profit-generating structure based on an era when generic drugs account for 80% of the market.
  17. FY2018-Q3RestatedAnnual report

    「The company established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company continues to set, in the second year of the Third Medium-Term Management Plan, the building of a profit-generating structure in an era when generic drugs account for 80% of the market as a priority.
  18. FY2018-Q2RestatedAnnual report

    「The company established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company has reiterated, in the second year of the Third Medium-Term Management Plan, its target of building a profit-generating structure in an era when generic drugs account for 80% of the market.
  19. FY2018-Q1RestatedAnnual report

    「1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market.」

    The company continues to set, in the second year of the Third Medium-Term Management Plan, its target of building a profit-generating structure based on an era when generic drugs account for 80% of the market.
  20. FY2017RestatedAnnual report

    「Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market.」

    The company has reiterated its target of building a profit-generating structure based on an era when generic drugs account for 80% of the market.
  21. FY2017-Q2RestatedAnnual report

    「The company established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company has reiterated its target of building a profit-generating structure in an era when generic drugs account for 80% of the market.
  22. FY2017-Q1RestatedAnnual report

    「The company established the following two medium-term visions under the Third Medium-Term Management Plan: 1. Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market. 2. Establish the foundation for a medical and nursing care coordination business and deepen its involvement in local healthcare.」

    The company has reiterated its target of building a profit-generating structure based on an era when generic drugs account for 80% of the market, even after the plan began.
  23. FY2016First statedAnnual report

    「Build a structure capable of generating profit even in an era when generic drugs account for 80% of the market.」

    Based on the spread of generic drugs, the company has set building a profit-generating structure as its medium-term vision.
Moved together

"Medical Cost-Containment Policies and Revisions to the Official Drug Price Standard" moved the same way as this thread, in the same document, in 2 of its 23 moves.

222★123
  1. ★This thread
  2. 1Medical Cost-Containment Policies and Revisions to the Official Drug Price Standard2×
  3. 2Impairment of Fixed Assets2×
  4. 3Business Suspension Caused by Natural Disasters and Accidents2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Vital Ksk Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
A Profit-Generating Structure in the Era of 80% Generic Drug Use | VITAL KSK HOLDINGS,INC. (3151) | Komori